Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 7/20 | 0.77 |
| ▸ | GABRB1 known ✓ | P18505 | 5/20 | 0.77 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 0.77 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.77 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.77 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.77 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.77 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.77 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.77 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | CA1 | P00915 | 2/20 | 0.77 |
| ▸ | CA2 | P00918 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | FAAH | O00519 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propofol SCHEMBL28576357 | 0.98 | GABRA1 (0.74) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL36245 | 0.88 | GABRA1 (1.00) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL2414429 | 0.88 | GABRA1 (1.00) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL10968616 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL8026569 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL4088686 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL10968613 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL1033835 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL5036811 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 | |
| Propofol SCHEMBL8935177 | 0.85 | GABRA1 (0.94) | GABRA1GABRB1GABRB2LMNAGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101780096-A | Propofol phosphate for injection and preparation method and application thereof | SHAANXI SYNTHETIC PHARMACEUTIC | 2010-07-21 | — | — | CN | claimed |
| US-11344499-B2 | Nanoparticles as delivery vehicles of active ingredients and methods for the production thereof | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2022-05-31 | — | — | US | disclosed |
| EP-3638214-B1 | NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE INGREDIENTS AND METHODS FOR THE PRODUCTION THEREOF | CONSIGLIO NAZIONALE RICERCHE (IT) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021078073-A1 | N-CONTAINING DERIVATIVE OF SUBSTITUTED PHENOL HYDROXY ACID ESTER, AND PREPARATION AND USE THEREOF | 四川大学华西医院 | 2021-04-29 | — | — | WO | disclosed |
| CN-112694414-A | N-containing derivative of substituted phenol hydroxy acid ester, preparation and application | 四川大学华西医院 | 2021-04-23 | — | — | CN | disclosed |
| US-20200206138-A1 | NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE INGREDIENTS AND METHODS FOR THE PRODUCTION THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2020-07-02 | — | — | US | disclosed |
| EP-3638214-A1 | NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE INGREDIENTS AND METHODS FOR THE PRODUCTION THEREOF | Consiglio Nazionale Delle Ricerche (IT) | 2020-04-22 | — | — | EP | disclosed |
| US-10561735-B2 | Solid formulations of liquid biologically active agents | PALADIN LABS INC. (CA) | 2020-02-18 | — | — | US | disclosed |
| CN-110655473-A | Alkyl substituted phenol carboxylate compound, preparation method and application | 重庆迈迪生医药科技有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-1817035-B1 | SOLID FORMULATIONS OF LIQUID BIOLOGICALLY ACTIVE AGENTS | PALADIN LABS INC (CA) | 2019-10-23 | — | — | EP | disclosed |
| EP-1615935-A1 | PHOSPHATE DERIVATIVES | Vital Health Sciences Pty Ltd. (AU) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092187-A1 | PHOSPHATE DERIVATIVES | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-10-28 | — | — | WO | disclosed |
| EP-1318798-A4 | WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR TREATMENT OF MIGRAINE | VYREX CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1075489-B1 | WATER-SOLUBLE PRODRUGS OF 2,6-DIISOPROPYLPHENOL ANALOGUES | VYREX CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-1318798-A1 | WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR TREATMENT OF MIGRAINE | VYREX CORPORATION (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6362234-B1 | HEADACHES | VYREX CORPORATION | 2002-03-26 | — | — | US | disclosed |
| WO-2002013810-A1 | WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR TREATMENT OF MIGRAINE | VYREX CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6254853-B1 | DRUGS WITH CARRIERS | VYREX CORPORATION | 2001-07-03 | — | — | US | disclosed |
| EP-1075489-A2 | WATER-SOLUBLE PRO-DRUGS OF 2,6-DIISOPROPYLPHENOL ANALOGUES | VYREX CORPORATION (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999058555-A2 | WATER-SOLUBLE PRO-DRUGS OF 2,6-DIISOPROPYLPHENOL ANALOGUES | VYREX CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |